Neo-adjuvant and adjuvant chemotherapy of gastric cancer

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  De Vita, Fernando ^a   Giuliani, F ^a   Galizia, G ^b   Belli, C ^a   Aurilio, G ^a   Santabarbara, G ^a   Ciardiello, F ^a   Catalano, G ^a   Orditura, M ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Adjuvant and neo adjuvant setting; Gastric cancer; Prognosis

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE DERIVATIVE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; SEMUSTINE; ANTINEOPLASTIC AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RELAPSE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG EFFICACY; GASTRECTOMY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; STOMACH CANCER; SURGICAL TECHNIQUE; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; META ANALYSIS; METHODOLOGY; PHASE 3 CLINICAL TRIAL; REVIEW; STOMACH TUMOR;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; HUMANS; META-ANALYSIS; NEOADJUVANT THERAPY; STOMACH NEOPLASMS;

EID: 35748929698     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm239     Document Type: Conference Paper

References (32)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543.
2. Levi F, Lucchini F, Negri E et al. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer 2004; 110: 155-169.
3. Levi F, Lucchini F, Gonzalez JR et al. Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 2004; 15: 338-345.
4. Engstrom PF, Lavin DT, Douglass HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group (EST 3275). Cancer 1985; 55: 1868-1873.
5. Coombes RC, Schein PS, Chilvers CED et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8: 1362-1369.
6. Arak A, Kull K. Factors influencing survival of patients after radical surgery for gastric cancer. Ann Oncol 1994; 33: 913-920.
7. Bonekamp JJ, Songun I, Hermans J et al. Randomized comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 345: 745-748.
8. Bonekamp JJ, Hermans J, Sasako M et al. Extended lymph node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
9. Hartgrink HH, Van de Velde CJH, Putter H et al. Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004; 22: 2069-2077.
10. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
11. Meyerhardt JA, Fuchs CS. Adjuvant therapy in gastric cancer: Can we prevent recurrences? Oncology 2003; 17: 714-722.
12. Hartgrink HH, Van de Velde CJH, Putter H et al. Neoadjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomized FAMTX trial. Eur J Surg Oncol 2004; 30: 643-649.
13. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
14. Roth AD. Curative treatment of gastric cancer: Towards a multidisciplinary approach? Crit Rev Oncol Hematol 2003; 46: 59-100.
15. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. Five years of follow-up of first British Stomach Cancer Group trial. Lancet 1989; 1: 571-574.
16. Krook JE, O'Connel MJ, Wieand HS et al. A prospective randomized evaluation of intensive course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458.
17. Haim N, Epelbaum R, Cohen Y, Robinson E. Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin and mitomycin-C (modified FAM). Cancer 1984; 54: 1999-2002.
18. Cullinan SA, Moertel GC, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric cancer: Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253: 2061-2067.
19. Hermans J, Bonekamp JJ, Bon MC et al. Adjuvant therapy after resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
20. Piedbois P, Buyse M. Meta-analysis need time collaboration and funding. J Clin Oncol 1994; 12: 878-879.
21. Pignon JP, Ducruex M, Rouger P. Meta-analysis of adjuvant chemotherapy in gastric cancer: A critical reappraisal. J Clin Oncol 1994; 12: 877-878.
22. Hermans J, Bonekamp H. In reply [letter]. J Clin Oncol 1994; 12: 879-880.
23. Earle CC, Maroun JA. Adjuvant chemotherapy after resection for gastric cancer in non-Asian patients. Revisiting a meta-analysis of randomized trials. Eur J Cancer 1999; 35: 1059-1064.
24. Mari M, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis for published randomized trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000; 11: 837-843.
25. Panzini I, Gianni L, Fattori PP et al. Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-27.
26. Janunger KG, Hafstrom L, Glimelius B. Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002; 168: 597-608.
27. Bajetta E, Buzzoni R, Mariani L et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomized study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 2002; 13: 299-307.
28. Di Costanzo F, Gasperoni S, Manzione L et al. Postoperative chemotherapy (CT) in resected gastric cancer (GC): Follow-up (FUP) vs PELF. Results of an Italian intergroup (GOIRC & GISCAD) study Proceedings of the 39th ASCO Meeting (Abstr 1189) Chicago, 31 May-3 June, 2003.
29. Bouchè O, Ychou M, Burtin P et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 2005; 16: 1488-1497.
30. Nitti D, Wils J, Dos Santos Guimares J et al. Randomized phase III trial of FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and ICCG. Ann Oncol 2006; 17: 262-269.
31. Colucci G, Giuliani F, Gebbia V et al. Epirubicin, folinic acid, fluorouracil and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM). Am J Clin Oncol 1999; 22: 262-266.
32. De Vita F, Giuliani F, Orditura M et al. Adjuvant chemotherapy with ELFE regimen in resected gastric cancer patients: A randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM). Ann Oncol; In press.